关于DDR抑制剂的解释性综述:它们的生物活性,合成途径和结构-活性关系关系
Sindhuja Sengupta1,2, Lalmohan Maji1,3, Pronoy Kanti Das1
1Integrated Drug Discovery Centre, Department of Pharmaceutical Chemistry, Acharya & BM Reddy College of Pharmacy, Bengaluru, 560107, Karnataka, India.
迪斯科伊丁域受体 (DDR) 是关键的氨酸激酶受体,与癌症和纤维化等疾病有关. 本综述详细介绍了DDR结构,信号传递和抑制剂,重点介绍了强效化合物64a和103a.
科学领域:
- 分子生物学分子生物学
- 生物化学 生化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 迪斯科伊丁域受体 (DDRs) 是氨酸激酶受体 (RTKs) 的一个子类,涉及到各种病理状况,包括癌症,纤维化和炎症性疾病.
- 尽管它们的作用已知,但DDR1和DDR2受体作为治疗点仍未得到充分探索,缺乏FDA批准的小分子抑制剂.
研究的目的:
- 为DDR解剖学,生理学和信号通路提供全面的概述.
- 审查DDR抑制剂的当前情况,重点关注它们的化学类,生物活性,选择性和结构-活性关系.
- 为潜在的治疗开发确定强大的DDR抑制剂.
主要方法:
- 文献综述和对DDR及其抑制剂的现有科学数据的汇编.
- 对DDR1和DDR2的结构特征和信号机制的分析.
- 评估各种DDR抑制剂类的进化发展和结构-活性关系.
主要成果:
- 该审查详细介绍了DDR1和DDR2的六个关键结构领域.
- 化合物64a和103a显示出显著的功效,IC50值分别为4.67nM (DDR1选择性) 和3.2nM (DDR2选择性).
- 目前正在进行大量的研究,以开发强效的DDR抑制剂.
结论:
- 迪斯科伊丁域受体代表了一个有前途的,但在很大程度上尚未开发的,用于治疗各种疾病的治疗干预的目标类别.
- 已发现的强效抑制剂,如64a和103a化合物,需要进一步研究药物开发.
- 对DDR结构,信号和抑制剂开发的持续研究对于解决未满足的医疗需求至关重要.
更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
10:24NMR-Based Activity Assays for Determining Compound Inhibition, IC50 Values, Artifactual Activity, and Whole-Cell Activity of Nucleoside Ribohydrolases
Published on: June 30, 2019
相关概念视频
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Drug-Receptor Interactions
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Principles of Drug Action
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
